(NASDAQ:CBAY) has 131 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These BG&G announces an investigation of CymaBay Therapeutics, Inc. (CBAY) for Following this news, CymaBay stock dropped $0.21 per share, or over 11%, 2 Mar 2020 of Securities Claims Against CymaBay Therapeutics, Inc. – CBAY On this news, CymaBay's stock price fell $5.04 per share, or over 45%, 14 Feb 2020 News and research before you hear about it on CNBC and others. Shareholders have suffered immensely with CBAY's stock down almost CymaBay Therapeutics Inc. (CBAY) Latest Stock News ... Get the latest CymaBay Therapeutics Inc. (CBAY) stock news and headlines to help you in your trading and investing decisions. CBAY Stock Price | CymaBay Therapeutics Inc. Stock Quote ...
Get breaking news and analysis on CymaBay Therapeutics, Inc. (CBAY) stock, price quote and chart, trading and investing tools. Prev Close 1.42, 52 Wk Low 1.21. Open 1.44, 52 Wk High 13.75. Day Low 1.43, Volume 441,936.00. Day High 1.53, Avg 10D Vol 1.8M (CBAY) Company Bio. Cymabay Therapeutics, Inc. focuses on developing therapies to treat metabolic diseases. The company was formerly known as Metabolex,
CBAY: Get the latest CymaBay Therapeutics stock price and detailed information including CBAY news, historical charts and realtime prices. CBAY -- Is Its Stock Price A Worthy Investment? Learn More. Cymabay Therapeutics, Inc. focuses on developing therapies to treat metabolic diseases. The company was formerly known as Metabolex, Inc. The company was … CBAY: Cymabay Therapeutics Inc - Stock Price, Quote ... - CNBC
CBAY Stock | CYMABAY THERAPEUTICS Stock Price Today ... CBAY: Get the latest CymaBay Therapeutics stock price and detailed information including CBAY news, historical charts and realtime prices. CBAY -- Is Its Stock Price A Worthy Investment? Learn More.
CymaBay Therapeutics (Nasdaq: CBAY) We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need. We are evaluating seladelpar in primary biliary cholangitis (PBC). The PBC program is on hold. CymaBay Therapeutics Inc. (CBAY) News Headlines - NASDAQ.com Dec 27, 2019 · CymaBay Therapeutics Inc. (CBAY) News – Find the latest company news headlines for CymaBay Therapeutics Inc. and all the companies you research at NASDAQ.com All News for CBAY : CymaBay Therapeutics Inc. - Zacks.com Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results. All News for CBAY : CymaBay Therapeutics Inc CymaBay Therapeutics Inc. - CBAY - Stock Price & News ... Real time CymaBay Therapeutics Inc. (CBAY) stock price quote, stock graph, news & analysis. Real time CymaBay Therapeutics Inc. (CBAY) stock price quote, stock graph, news & analysis.